Endovascular Engineering

Executive Summary

Endovascular Engineering is a private medical device company headquartered in San Francisco, developing the Hēlo™ Thrombectomy System for the treatment of acute ischemic stroke and potentially other vascular occlusions. The system's unique funnel design combines a self-expanding distal opening for large bore clot engagement with a small profile catheter, enabling navigation through tortuous anatomy. Its dual-action technology simultaneously agitates and aspirates clot material, aiming to improve recanalization rates while minimizing distal embolization. The company has not disclosed total funding or valuation but appears to be in the clinical or early commercialization phase, targeting a significant unmet need in thrombectomy where current devices often compromise between deliverability and efficacy. With a focus on innovation in neurointervention, Endovascular Engineering represents a compelling opportunity in the cardiovascular device space, though it faces competition from established players like Medtronic, Stryker, and Johnson & Johnson. The company's progress hinges on regulatory clearance and clinical evidence generation. As a private entity with limited public data, conviction is moderate pending demonstration of safety and efficacy in pivotal studies. The upcoming catalysts are critical for de-risking the technology and unlocking partnership or acquisition interest. If successful, the Hēlo System could capture share in the growing thrombectomy market, driven by expanding indications and aging demographics.

Upcoming Catalysts (preview)

• Q3 2026FDA 510(k) Clearance for Hēlo Thrombectomy System70% success
• Q2 2026Completion of Pivotal Clinical Trial Enrollment80% success
• Q4 2026Strategic Partnership or Distribution Agreement with Major Cardiovascular Company50% success